Loading
Atrium Therapeutics, Inc. Stock: price and insider trades · United States
US·Mcap US$133.8M
Atrium Therapeutics, Inc.: what insiders have been doing
Every trade that managers of Atrium Therapeutics, Inc. disclose to SEC (Form 4) is tracked on this page. The last twelve months, up to 18 October 2026, brought 14 filings signed by 8 insiders.
None of the filings is a plain purchase or sale on the open market; they cover grants, option exercises and other movements. Because grants and exercises are largely decided by remuneration plans, they are not counted as purchases here.
For context, the typical company on the same exchange (median of 5,811 companies) published 19 filings over the same period, against 14 filings here.
Over the last twelve months, not one insider purchase of Atrium Therapeutics, Inc. stock was filed. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 4 days. For comparison, the SEC allows two business days to file a Form 4.
For comparison within the same market, see the insider buying recorded at GameStop Corp. and Heico Corp. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
14
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
n/a
n/a
Analyst consensus: bullish or bearish?
Analysts rate Atrium Therapeutics, Inc. Strong Buy (bullish), based on 4 analysts. Average price target: US$25.00.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$7.82
Analyst consensus
4 analystsStrong buy
US$25.00Target US$25.00(+220%)US$25.00
Income statement
RevenueUS$18.6M
EBITDA-US$76.5M-411% margin
Net income-US$76.7M-184.1% margin
Valuation
PER (forward)-1.2x
P/Book0.6x
Balance sheet & cash
Market capUS$133.8M
Total debtUS$3.7M
Free Cash Flow-US$42.6M
Debt / Equity1%
Profitability & ownership
% insiders4.2%
% institutions84.9%
Last declaration on 22 September 2026
Declarations14 total
2,375 shares@ US$8.950.015% mcap100.0% of flowCommon StockSEC:0001193125-26-397948:0
126,418 shares@ US$8.950.80% mcap100.0% of flowCommon StockSEC:0001193125-26-397951:0
22,812 shares@ US$8.950.14% mcap100.0% of flowCommon StockSEC:0001193125-26-397955:0
21,459 shares@ US$8.950.14% mcap100.0% of flowCommon StockSEC:0001193125-26-397967:0
8,320 shares@ US$8.950.053% mcap100.0% of flowCommon StockSEC:0001193125-26-397936:0
6,742 shares@ US$8.950.043% mcap100.0% of flowCommon StockSEC:0001193125-26-397941:0
11,632 shares@ US$8.950.074% mcap100.0% of flowCommon StockSEC:0001193125-26-397944:0
11,216 shares@ US$8.950.071% mcap100.0% of flowCommon StockSEC:0001193125-26-397971:0
30,000 shares0Common StockSEC:0001193125-26-170906:0
30,000 shares0Common StockSEC:0001193125-26-170907:0
102,500 shares0Common StockSEC:0001193125-26-170914:0
30,000 shares0Common StockSEC:0001193125-26-170960:0
30,000 shares0Common StockSEC:0001193125-26-170963:0
30,000 shares0Common StockSEC:0001193125-26-170964:0
14 of 14 declarations
About Atrium Therapeutics, Inc.
Atrium Therapeutics, Inc. is a company focused on developing innovative treatments for cardiovascular diseases. It is listed on the NASDAQ under the ticker symbol ATRM.
Recent ranked signals on the same market
Purchases our model currently ranks for the recommendations list.
All recommendations
